La soumission des abstracts est prolongée jusqu'au 26 février !
ISHEID 2023
Dear Friends, dear Colleagues,
The understanding of HIV and hepatitis infections continues to grow rapidly, especially regarding our ability to develop novel prevention and therapeutic strategies that will lead to the reduction of new infections. The burden of non-communicable diseases in HIV infected subjects implicates a multidisciplinary approach of the infection and the need of close interactions with specialists from other disciplines.
ISHEID dedicates a privileged place to state-of-the-art presentations, as well as to debates among experienced and younger investigators regarding new data and their implications.
This event has invited lectures by European and international leaders, many oral abstract and poster presentations, and educational workshops, as well as overviews of comorbidities by specialists of each field.
It is unique in its approach, as it engages basic scientists and clinicians from the HIV, hepatitis and emerging infectious diseases fields, as well as leading scientists involved in comorbidities.
We wish you a pleasant congress.
Christina PSOMAS, Patrick PHILIBERT & Alain LAFEUILLADE
on behalf of the steering committee
ISHEID 2023
We are pleased to welcome you to ISHEID, the International Symposium on HIV and Emerging Infectious Diseases.
The understanding of HIV and hepatitis infections continues to grow rapidly, especially regarding our ability to develop novel prevention and therapeutic strategies that will lead to the reduction of new infections. The burden of non-communicable diseases in HIV infected subjects implicates a multidisciplinary approach of the infection and the need of close interactions with specialists from other disciplines.
ISHEID 2023 dedicates a privileged place to state-of-the-art presentations, as well as to debates among experienced and younger investigators regarding new data and their implications.
This event has invited lectures by European and international leaders, many oral abstract and poster presentations, and educational workshops, as well as overviews of comorbidities by specialists of each field.
It is unique in its approach, as it engages basic scientists and clinicians from the HIV, hepatitis and emerging infectious diseases fields, as well as leading scientists involved in comorbidities.
We wish you a pleasant congress.
Christina PSOMAS, Patrick PHILIBERT & Alain LAFEUILLADE
on behalf of the steering committee
MONDAY, MAY 17, 2021
LESSONS FROM COVID-19: PITFALLS AND PROMISE (In partnership with the EACS Young Investigators) / LES LEÇONS DE LA COVID-19 : PIÈGES ET PROMESSES (en partenariat avec les jeunes chercheurs de l’EACS)
Chairs: Christina PSOMAS, European Hospital, Marseille, France Annemarie WENSING, University Medical Center Utrecht, Netherlands Moderator: Tristan BARBER, Royal Free London NHS Foundation Trust, London, England
HIV and COVID-19 / VIH et COVID-19
Christoph SPINNER, Munich, Germany
Research pitfalls; what COVID has taught us / Les pièges de la recherche : ce que le COVID-19 nous apprend
Laura WATERS, London, England
HIV CURE / LA GUÉRISON DU VIH
Chairs: Sabine KINLOCH, Institute of Immunity & Transplantation, London, England Jean-Pierre ROUTY, McGill University Health Centre, Montreal, Canada
Therapeutic simplification strategies in HIV infection and new ART strategies (2DR, triple regimen) / La simplification des stratégies thérapeutiques et les stratégies antirétrovirales chez les patients atteints par le VIH (2DR, triple regimen)
Jeff MURRY, Foster City, USA
Dual therapy against tritherapy: inflammation Vs toxicity / Les bithérapies contre les trithérapies : inflammation Vs toxicité
Christina PSOMAS, Marseille, France
Casper ROKX, Rotterdam, the Netherlands
Notice: Undefined index: text in /home/peisheid/www/wp-content/plugins/timeline/inc/jour1.php on line 269
Dual therapy against tritherapy: inflammation Vs toxicity / Les bithérapies contre les trithérapies : inflammation Vs toxicité
BEST ORAL COMMUNICATIONS / MEILLEURES COMMUNICATIONS ORALES
Chairs: Guido POLI, Vita-Salute San Raffaele University, Milano, Italy Santiago MORENO, Hospital Ramón y Cajal, Madrid, Spain
O1. Impact of early antiretroviral therapy on tissue resident myeloid cells in the liver and lung of SIV-infected rhesus macaques
Authors: J. CLAIN, H. RABEZANAHARY, G. RACINE, G. BENMADID-LAKTOUT, O. ZGHIDI-ABOUZID, J. ESTAQUIER
Quebec University Hospital, Laval University, Research Center, Quebec - Canada
O2. Sexual satisfaction in women living with HIV. Are they the forgotten ones?
Authors: L. GONZÁLEZ RODRÍGUEZ1, J. BALIÑAS2, R. SCHULTZE3, L. LABAJO3, M.D.G. MUÑOZ3, Á. MENA2
1Obstetrics And Gynecology Service, Álvaro Cunqueiro University Hospital, Vigo - Spain
2Infectious Pathology Unit, A Coruña University Complex, A Coruña - Spain
3Infectious Pathology Unit, Álvaro Cunqueiro University Hospital, Vigo - Spain
O3. Influence of Hepatitis E virus genetic variability on the viral circulation between humans and environment
Authors: E. SCHVOERER1, C. HARTARD1, H. FENAUX1, A. DE ROUGEMONT2, E. LAUGEL1, S. BERGER1,J.P. BRONOWICKI3, I. BERTRAND4
1Nancy University Hospital, Laboratory of Virology, Vandœuvre-Lès-Nancy - France
2Dijon University Hospital, Laboratory of Virology, Dijon - France
3Nancy University Hospital, Hepato-Gastroenterology, Vandoeuvre Les Nancy - France
4 Lcpme (laboratoire De Chimie Physique Et Microbiologie Pour Les Matériaux Et L'environnement), Umr 7564Cnrs-Ul, Campus Santé Brabois, Vandoeuvre Les Nancy - France
O4. Effect of Metformin in non-diabetic people living with HIV: weight loss, decrease in inflammation and modification of the gut microbiota
Authors: S. ISNARD1, J. LIN1, T. VARIN2, A. MARETTE2, D. PLANAS3, C. VAN DER LEY4, P. ANCUTA3, J.P. ROUTY1
1Mcgill University Health Centre, Montreal - Canada
2Laval University, Québec - Canada
3 Montreal University, Montreal - Canada
4University Of Groningen, Groningen - Netherlands
O5. Extensive proteomic and transcriptomic changes quench the TCR/CD3 activation signal in latently HIV-1 infected T cells
Authors: E. CARLIN, B. GREER, A. DUVERGER, F. WAGNER, D. MOYLAN, A. DALECKI, S. SABBAJ, O. KUTSCH UAB, Birmingham - United States
DP1. Tracing the patterns of HIV-1 transmission among individuals with different diagnosis status in Greece
Authors: E-G. KOSTAKI1, S. LIMNAIOS1, S. PATRINOS2, D. CHATZIDIMITRIOU3, G. MAGIORKINIS1, L. SKOURA3, V. SYPSA1, A. HATZAKIS1, D. PARASKEVIS1
1Department Of Hygiene, Epidemiology And Medical Statistics, Medical School, National And Kapodistrian University Of Athens, Athens - Greece
2Hellenic Center For Diseases Control And Prevention, Marousi - Greece
3 National Aids Reference Center Of Northern Greece, Department Of Microbiology, Aristotle University Medical School, Thessaloniki - Greece
DP2. Identification of fast-growing HIV-1 transmission clusters in Spain and its potential application in Public Health
Authors: H. GIL, E. DELGADO, S. BENITO, M. SÁNCHEZ, J. CAÑADA, E. GARCÍA-BODAS, M.M. THOMSON,
Spanish group for the study of new HIV diagnoses
National Microbiology Centre. Carlos III Health Institute, Majadahonda - Spain
DP3. No impact of SARS-CoV-2 on the Activation Status of ART+HIV+ Patients
Authors: M. NIKOLOVA1, R. EMILOVA1, Y. TODOROVA1, N. YANCHEVA2, I. ALEXIEV3, R. GROZDEVA2, D. STRASHIMIROV2,N. KUYCHUKOVA2
1Nrl Of Immunology, National Centre Of Infectious And Parasitic Diseases, Sofia - Bulgaria
2Specialized Hospital for Active Treatment of Infectious and Parasitic Diseases, Sofia - Bulgaria3Nrl Of HIV, National Center of Infectious and Parasitic Diseases, Sofia - Bulgaria
DP4. Factors associated with willingness to participate in end-of-life cure research: perspectives from People Living with HIV
Authors: D. LESSARD1, M. BILODEAU2, P. KEELER3, J.P. ROUTY4, E.A. COHEN5, K. DUBÉ6, B. LEBOUCHÉ1,C. COSTINIUK4
1Canadian Institutes Of Health Research Strategy For Patient-Oriented Research Mentorship Chair In Innovative Clinical Trials, Montreal - Canada
2Ontario Aids Network, Toronto - Canada
3Aids Community Care Montreal, Montreal - Canada
4Research Institute of the Mcgill University Health Centre, Montreal - Canada
5Montreal Institute of Clinical Research, Department of Microbiology, Infectiology and Immunology, Montreal University,Montreal - Canada
6Public Health Leadership Program, University Of North Carolina At Chapel Hill And Chapel Hill And Gilings School Of Global Public Health, Chapel Hill - USA
DP5. Fibrosis regression in HIV-HCV coinfected patients treated by DAAs
Authors: G. LAURICHESSE1, P. JAFFEUX2, A. MIRAND3, N. MROZEK1, M. VIDAL1, V. CORBIN1, H. LAURICHESSE1,C. JACOMET1
1Clermont-Ferrand University Hospital, Infectious Diseases, Clermont-Ferrand - France
2Clermont-Ferrand University Hospital, Statistics, Clermont-Ferrand - France
3Clermont-Ferrand University Hospital, Virology, Clermont-Ferrand - France
DP6. Differential Serotyping of HEV genotype 1 and 3
Authors: M. SHATA1, E. ABDEL-HAMEED1, S. ROUSTER1, H. HETTA2, K. SHERMAN3
1University of Cincinnati, Cincinnati - USA
2Department of Medical Microbiology and Immunology, Faculty of Medicine,Assiut University, Assiut - Egypt
3University of Cincinnati, Internal Medicine, Digestive Dis., Cincinnati - USA
TUESDAY, MAY 18, 2021
VACCINES / LES VACCINS
Moderator: Diana FINZI, National Institute of Health, Bethesda, USA Jean-Pierre ROUTY, McGill University Health Centre, Montreal, Canada
Vaccines update for HIV and immunosuppressed patients / Calendrier vaccinal pour les PVVIH et les patients immunodéprimés
Anna-Maria GERETTI, London, England
Post-infection Vs post-vaccinal SARS-CoV-2 immunity: challenges and reality / Post-infection Vs l’immunité acquise grâce au vaccin : défi et réalité
Olivier SCHWARTZ, Paris, France
QUALITY OF LIFE MATTERS! TAILOR CARE TO OPTIMIZE IT IN PLWH
Symposium sponsored by MSD/ symposium parrainé par MSD
Moderator: Jonathan Schapiro, Sheba, ISR
Welcome and introduction
Jonathan Schapiro, Sheba, ISR
Future of NNRTIs: State of the ART of NNRTI resistance
Jonathan Schapiro, Sheba, ISR
Tailoring care for the body
Paddy Mallon, Dublin, IRL
Tailoring care for women with HIV
Karine Lacombe, Paris, FRA
Q&A
Notice: Undefined index: text in /home/peisheid/www/wp-content/plugins/timeline/inc/jour2.php on line 269
Welcome and introduction
Future of NNRTIs: State of the ART of NNRTI resistance
Tailoring care for the body
Tailoring care for women with HIV
Q&A
COMORBITIES AND MICROBIOTE / COMORBIDITÉS ET MICROBIOTE
Chairs: Jose Ignacio BERNARDINO, La Paz University Hospital, Madrid, Spain Christina PSOMAS, European Hospital, Marseille, France
The microbiome / Le microbiome
Sergio SERRANO VILLAR, Madrid, Spain
NASH and obesity and weight gain in hepatitis and HIV / La NASH chez les personnes atteintes par une hépatite ou par le VIH
Paddy MALLON, Dublin, Ireland
Role of hepatotropic viruses in the pathogenesis of cancer in PLWH / Le rôle des virus hépatotropes dans la pathogénèse du cancer chez les PVVIH
Alvaro MENA, Coruna, Spain
O6. Myocardial abnormailties in HIV: Insights from Cardiac Magnetic Resonacne Imaging (MRI)
Authors: G. MANMATHAN1, L. CHACKO2, R. MURKI2, T. KOTECHA2, C. LITTLE2, T. BARBER1,S. KINLOCH1, M. JOHNSON1, R. RAKHIT2
1Royal Free Hospital, London - United Kingdom
2University College London, London - United Kingdom
O7. Cardiomyopathy, pulmonary hypertension and myocarditis not as prevalent in well controlled
HIV: H-ART to Heart study
Authors: G. MANMATHAN, N. NGWU, J. JOHNSON, C. LITTLE, T. KOTECHA, M. JOHNSON, R. RAKHIT
Royal Free Hospital, London - United Kingdom
DP7. Nlrp3 inflammasome activation in peripheral blood leukocytes from HIV-infected patients and its contribution to chronic inflammation
Authors: V. NUNES CORDEIRO LEAL, E.C. DOS REIS, A. PONTILLO
University Of Sao Paulo, Sao Paulo - Brazil
WEDNESDAY, MAY 19, 2021
HOW TO END THE HIV PANDEMIC? / COMMENT ÉRADIQUER LA PANDÉMIE DE VIH ?
Chairs: Caroline SABIN, Royal Free Campus, London - England Christina PSOMAS, European Hospital, Marseille, France
London experience / L’expérience londonienne
Alison BROWN, London, England
Fast track cities, where are we? / Les fast-track cities : où en sommes-nous ?
Bertrand AUDOIN, Paris, France
BEYOND VIRAL SUPPRESSION, WHAT ARE THE CHALLENGES IN THE MANAGEMENT OF HIV INFECTION IN 2021?
Symposium sponsored by GILEAD/ symposium parrainé par GILEAD
Moderator: Christina Psomas
Inflammation and Immune markers
Christina Psomas, Montpellier, FRA
Sleep disorders and depression
Anne Moroy, Lille, FRA
Prevention and management of drug drug interactions
Olivier Robineau, Tourcoing, FRA
Notice: Undefined index: text in /home/peisheid/www/wp-content/plugins/timeline/inc/jour3.php on line 269
Inflammation and Immune markers
Sleep disorders and depression
Prevention and management of drug drug interactions
SARS-COV-2
Chairs: Valérie POURCHER, Hôpital de la Pitié-Salpêtrière, Paris, France Hervé TISSOT DUPONT, Aix-Marseille University, Marseille, France
Neurological complications of COVID-19, in acute disease and long-term / Les complications neurologiques de la COVID-19, dans les maladies aiguës et au long cours
Arvid EDÉN, Gothenburg, Sweden
Genetic determinants of COVID-19 disease severity / Les déterminants génétiques qui ont un impact sur la gravité de la COVID-19
Manuel CORPAS, Cambridge, England
DP8. Viral rebound (VR) 14 years after discontinuation of antiretroviral therapy (ART)
Authors: S. KINLOCH-DE LOES1, L. VANDEKERCKHOVE2, F. BURNS3, M. JOHNSON1
1Royal Free Hospital, London - United Kingdom
2University of Ghent, Ghent - Belgium
3Ucl, London - United Kingdom
DP9. Frailty phenotype is associated with antiretroviral exposure among older persons living with HIV
Authors: G. FELKER1, P. ENEL1, N. PETIT1, I. RAVAUX1, A. DARQUE1, F. RETORNAZ2
sup1Public University Hospital of Marseille, Marseille - France
2Department Of Public Health, Self-Perceived Health Assessment Research Unit Ea3279,Aix-Marseille University, Marseille - France
THURSDAY, MAY 20, 2021
CLIMATE AND SOCIO-POLITICAL CHANGES, HIV AND EPIDEMICS / CHANGEMENTS CLIMATIQUES ET SOCIO-POLITIQUES, VIH ET ÉPIDÉMIES
Chairs: Stephano VELLA, Superior Health Institute, Rome, Italy Ferdinand WIT, Academic Medical Center Amsterdam, Netherlands
HIV and global health in the era of coronavirus
Stefano VELLA, Rome, Italy
HTLV-1 has become a new STI
Carmen DE MENDOZA, Madrid, Spain
LONG-TERM VIROLOGICAL AND CLINICAL IMPACT OF DUAL THERAPY / IMPACT VIROLOGIQUE ET CLINIQUE LONG TERME DE LA BITHÉRAPIE
Symposium sponsored by VIIV HEALTHCARE/ symposium parrainé par VIIV HEALTHCARE
Moderator: Christine KATLAMA, Paris, FRA
Dual therapies: what are the impacts on HIV reservoirs? / Bithérapies : quels sont les impacts sur les réservoirs du VIH ?
Véronique Avettand-Fenoel. MCU-PH - UNIVERSITE PARIS , CHU Necker-Enfants Malades, Paris, FRA
What is the impact of long term dual therapy on bone, renal,inflammation and metabolics? / Quel est l'impact de la bithérapie à long terme sur l'os, le rein,l'inflammation et le métabolisme ?
Laura Waters, FRCP MD. Mortimer Market Centre, CNWL, London, UK
Notice: Undefined index: text in /home/peisheid/www/wp-content/plugins/timeline/inc/jour4.php on line 269
Dual therapies: what are the impacts on HIV reservoirs? / Bithérapies : quels sont les impacts sur les réservoirs du VIH ?
What is the impact of long term dual therapy on bone, renal,inflammation and metabolics? / Quel est l'impact de la bithérapie à long terme sur l'os, le rein,l'inflammation et le métabolisme ?
SEXUALLY TRANSMITTED INFECTIONS / LES INFECTIONS SEXUELLEMENT TRANSMISSIBLES
Chairs: Patricia ENEL, Aix-Marseille University, Marseille, France Patrick PHILIBERT, European Hospital, Marseille, France
Impact of COVID on sexual behaviour/risks/testing/ L'impact de la COVID sur les comportements/risques/essais sexuels
Cath MERCER, London, England
New challenges in STIs: M. Genitalium, XDR N.gonorrhoeae / Les nouveaux défis parmi les IST : M. Genitalium, XDR N.gonorrhoeae
Vicente SORIANO, Madrid, Spain
O8. Sexual Transmission of HTLV-1 and expanded spectrum of clinical manifestations
Authors: V. SORIANO1, J.M. RAMOS2, H. PINARGOTE2, C. DE MENDOZA3, A. SPANISHH T L V NETWORK3
1Unir Health Sciences School & Medical Center, Madrid - Spain
2General University Hospital & Miguel Hernandez University, Alicante - Spain
3Puerta De Hierro University Hospital & San Pablo University-Ceu, Madrid - Spain
DP10. HIV-2 in Spain - steadily increasing and new challenges
Authors: V. SORIANO1, T. CABEZAS2, E. CABALLERO3, A.B. LOZANO2, C. DE MENDOZA4
1Unir Health Sciences School & Medical Center, Madrid - Spain
2Hospital De Poniente, Almeria - Spain
3Hospital Vall D'hebron, Barcelona - Spain
4Puerta De Hierro Research Institute, Madrid - Spain
Ouverture des
inscriptions
Ouverture de la
soumission des abstracts
Fin du tarif préférentiel
d'inscription
Fermeture de la soumission
des abstracts
Notification de statut
des abstracts
